Phospho-HER3 (Tyr1197)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 3218R
英文名称Phospho-HER3 (Tyr1197)
中文名称磷酸化HER3抗体
别 名Her3/ErbB3(phospho-Tyr1197); p-HRE3 (Tyr1197); ErbB 3 (phospho Y1197); ERBB3; c erbB 3; c erbB3; ERBB3 protein; erbB3 S; Glial growth factor receptor; HER 3; HER3; LCCS2; MDA BF 1; MGC88033; p180 ErbB3; p45 sErbB3; p85 sErbB3; proto-oncogene-like protein c ErbB 3; proto-oncogene-like protein c ErbB3; receptor tyrosine protein kinase ERB3; Receptor tyrosine protein kinase erbB 3; Receptor tyrosine protein kinase erbB3; Tyrosine kinase type cell surface receptor HER3; ERBB3_HUMAN.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 **学 信号转导 生长因子和** 激酶和磷酸酶 细胞膜受体 G蛋白偶联受体 肿瘤细胞生物标志物
抗体来源Rabbit
克隆类型Polyclonal
Phospho-HER3 (Tyr1197)抗体交叉反应 Human, Mouse, Rat,
产品应用IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量148kDa
细胞定位细胞膜 分泌型蛋白
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human HER3 around the phosphorylation site of Tyr1197 [EE(p-Y)EY]:EE(p-Y)EY
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-HER3 (Tyr1197)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
ErbB3 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. ErbB3 is a membrane-bound protein which has a neuregulin binding domain but not an active kinase domain. It can therefore bind this ligand but cannot convey a signal into the cell via protein phosphorylation. However it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers including prostate, bladder and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. Isoform 2 lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported but they have not been thoroughly characterized. Defects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2); also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord.
Function:
Binds and is activated by neuregulins and NTAK.
Subunit:
Monomer and homodimer. Heterodimer with each of the other ERBB receptors (Potential). Interacts with CSPG5, PA2G4, GRB7 and MUC1.
Subcellular Location:
Isoform 1: Cell membrane; Single-pass type I. membrane protein. Isoform 2: Secreted.
Tissue Specificity:
Epithelial tissues and brain.
Post-translational modifications:
Ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase. Subject to autophosphorylation.
DISEASE:
Defects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2) [MIM:607598]; also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. The LCCS2 syndrome is characterized by multiple joint contractures, anterior horn atrophy in the spinal cord, and a unique feature of a markedly distended urinary bladder. The phenotype suggests a spinal cord neuropathic etiology.
Similarity:
Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain.
SWISS:
P21860
Gene ID:
2065
Phospho-HER3 (Tyr1197)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-HER3 (Tyr1197)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 CYP3A1 细胞色素CYP3A1抗体
合格 DBPA 冷休克蛋白DBPA抗体
合格 PKC delta 蛋白激酶C亚性D型抗体
合格 合格 TLR4 Toll样受体4抗体
合格 TLR4 Toll样受体4抗体
合格 Cyclin D1 周期素D1抗体
合格 Beta catenin β-连环蛋白/β-连环素/β链接素抗体
合格 合格 Beta catenin β-连环蛋白/β-连环素/β链接素抗体
合格 iNos/Nos-2 一氧化氮合成酶-2（诱导型）抗体
合格 GPM6B 神经细胞膜糖蛋白M6b抗体
合格 合格 phospho-beta Catenin (Ser37) 磷酸化β-连环蛋白/β-连环素/β链接素抗体
合格 Phospho-Beta-Catenin (Ser552) 磷酸化β连环素蛋白抗体
合格 合格 phospho-beta Catenin (Ser33) 磷酸化β-连环蛋白/β-连环素/β链接素抗体
合格 Nestin 巢蛋白/神经上皮干细胞蛋白抗体
合格 eNOS 一氧化氮合成酶-3（内皮型）抗体
合格 合格 AQP9 水通道蛋白-9抗体
合格 PI 3 Kinase p85 alpha 磷脂酰肌醇激酶抗体
合格 Caspase-8 subunit p10 半胱氨酸蛋白酶8抗体
合格 Caspase-8 subunit p10 半胱氨酸蛋白酶8抗体
合格 NRXN3 轴突蛋白3抗体
合格 SNAIL Snail蛋白抗体
合格 Caspase-1 P10 天冬氨酸-胱氨酸特异性蛋白酶家族抗体
合格 N-cadherin N-钙粘附分子抗体
合格 合格 OPG 骨保护蛋白/护骨素抗体
合格 Androgen receptor 雄**受体抗体
合格 Integrin beta 1/CD29 整合素β1/Integrin β1抗体
合格 Integrin beta 1/CD29 整合素β1/Integrin β1抗体
合格 合格 HMGB1 高迁移率族蛋白B1抗体
合格 C peptide (human) 人C-肽抗体
合格 合格 CD20 CD20抗体
合格 合格 CD20 CD20抗体
合格 合格 phospho-beta catenin (Tyr142) 磷酸化β 连环素蛋白抗体